Compare $EGRX vs $INAB | Chartloom

Compare

$EGRX vs $INAB

Eagle Pharmaceuticals Inc · IN8bio Inc

EGRX

Eagle Pharmaceuticals Inc

INAB

IN8bio Inc

Compare $EGRX vs $INAB

Comparing Eagle Pharmaceuticals Inc and IN8bio Inc

EGRXEagle Pharmaceuticals Inc

INABIN8bio Inc

EGRXEagle Pharmaceuticals Inc

Market cap

$13M

P/E (TTM)

1.06x

Forward P/E (NTM)

0.25x

Forward P/S (NTM)

0.05x

Rev growth (TTM)

-5.4%

YTD performance

185.3%

52W performance

49.2%

FCF yield

-74.5%

INABIN8bio Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.5%

52W performance

-44.4%

FCF yield

-110.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EGRX

INAB

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

INAB

IN8bio Inc

Market Cap

EGRX$13M

INAB$13M

Enterprise Value

EGRX$67M

INAB$-5M

Price

EGRX$0.97

INAB$1.34

P/E Ratio

EGRX1.06x

INABN/A

P/S Ratio

EGRX0.05x

INAB0.00x

EV/Sales

EGRX0.26x

INAB0.00x

EV/EBITDA

EGRX1.07x

INAB0.00x

P/B Ratio

EGRX0.05x

INAB0.75x

P/FCF Ratio

EGRXN/A

INABN/A

EV/FCF

EGRX-7.18x

INAB0.32x

PEG Ratio

EGRXN/A

INABN/A

Forward P/E (NTM)

EGRX0.25x

INABN/A

Forward P/S (NTM)

EGRX0.05x

INABN/A

Revenue (TTM)

EGRX$258M

INAB$0

Revenue Growth (YoY)

EGRX-5.4%

INABN/A

Forward Rev Growth

EGRX0.0%

INAB1211.4%

Gross Margin (TTM)

EGRX69.9%

INAB0.0%

Operating Margin (TTM)

EGRX14.0%

INAB0.0%

EBITDA Margin (TTM)

EGRX24.5%

INAB0.0%

Net Margin (TTM)

EGRX4.7%

INAB0.0%

FCF Margin (TTM)

EGRX-3.6%

INABN/A

Net Income (TTM)

EGRX$12M

INAB$-19M

FCF (TTM)

EGRX$-9M

INAB$-15M

EPS (TTM)

EGRX$0.92

INAB-$0.96

ROE (TTM)

EGRX5.0%

INAB-9118.0%

ROA (TTM)

EGRX3.0%

INAB-7693.0%

ROIC (TTM)

EGRX3.9%

INAB-9006.0%

Cash

EGRX$15M

INAB$18M

Debt

EGRX$70M

INAB$126K

Net Cash/Debt

EGRX$-55M

INAB$18M

Current Ratio (TTM)

EGRX2.16x

INAB8.21x

Quick Ratio (TTM)

EGRX1.52x

INAB8.13x

Debt/Equity (TTM)

EGRX0.28x

INAB0.01x

Debt/Assets (TTM)

EGRX0.0%

INAB0.0%

Interest Coverage (TTM)

EGRXN/A

INABN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

INAB0.00x

Beta

EGRX0.88

INAB0.24

52W Performance

EGRX49.2%

INAB-44.4%

YTD Performance

EGRX185.3%

INAB-45.5%

% from 52W High

EGRX-74.9%

INAB-50.9%

% from 52W Low

EGRX88081.8%

INAB52.3%

Asset Turnover (TTM)

EGRX0.64x

INAB0.00x

FCF Yield (TTM)

EGRX-74.5%

INAB-110.6%

Earnings Yield (TTM)

EGRX96.0%

INAB-141.4%

Dividend Yield (TTM)

EGRXN/A

INABN/A

Rule of 40

EGRX-9.0

INAB0.0

EV/GP/RG

EGRXN/A

INABN/A

Ticker research

View EGRX research View INAB research

Metric	EGRX Eagle Pharmaceuticals Inc	INAB IN8bio Inc
Market & Valuation
Market Cap	$13M	$13M
Enterprise Value	$67M	$-5M
Price	$0.97	$1.34
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.00x
EV/Sales	0.26x	0.00x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	0.75x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	0.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	N/A
Revenue & Growth
Revenue (TTM)	$258M	$0
Revenue Growth (YoY)	-5.4%	N/A
Forward Rev Growth	0.0%	1211.4%
Profitability
Gross Margin (TTM)	69.9%	0.0%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	0.0%
Net Margin (TTM)	4.7%	0.0%
FCF Margin (TTM)	-3.6%	N/A
Net Income (TTM)	$12M	$-19M
FCF (TTM)	$-9M	$-15M
EPS (TTM)	$0.92	-$0.96
ROE (TTM)	5.0%	-9118.0%
ROA (TTM)	3.0%	-7693.0%
ROIC (TTM)	3.9%	-9006.0%
Financial Health
Cash	$15M	$18M
Debt	$70M	$126K
Net Cash/Debt	$-55M	$18M
Current Ratio (TTM)	2.16x	8.21x
Quick Ratio (TTM)	1.52x	8.13x
Debt/Equity (TTM)	0.28x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	0.24
52W Performance	49.2%	-44.4%
YTD Performance	185.3%	-45.5%
% from 52W High	-74.9%	-50.9%
% from 52W Low	88081.8%	52.3%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	0.00x
FCF Yield (TTM)	-74.5%	-110.6%
Earnings Yield (TTM)	96.0%	-141.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View EGRX research	View INAB research

Valuation

P/E Ratio

EGRX

1.06x

P/S Ratio

INAB

0.00x

EGRX

0.05x

EV/FCF

EGRX

-7.18x

INAB

0.32x

Growth & revenue

Revenue Growth TTM

EGRX

-5.4%

Forward Revenue Growth

INAB

1211.4%

EGRX

0.0%

Profitability & performance

Gross Margin

EGRX

69.9%

INAB

0.0%

ROE

EGRX

5.0%

INAB

-9118.0%

FCF Yield %

EGRX

-74.5%

INAB

-110.6%

52-Week Performance

EGRX

49.2%

INAB

-44.4%

Detailed metrics comparison

EGRX

Eagle Pharmaceuticals Inc

INAB

IN8bio Inc

Market Cap

EGRX$13M

INAB$13M

Enterprise Value

EGRX$67M

INAB$-5M

Price

EGRX$0.97

INAB$1.34

P/E Ratio

EGRX1.06x

INABN/A

P/S Ratio

EGRX0.05x

INAB0.00x

EV/Sales

EGRX0.26x

INAB0.00x

EV/EBITDA

EGRX1.07x

INAB0.00x

P/B Ratio

EGRX0.05x

INAB0.75x

P/FCF Ratio

EGRXN/A

INABN/A

EV/FCF

EGRX-7.18x

INAB0.32x

PEG Ratio

EGRXN/A

INABN/A

Forward P/E (NTM)

EGRX0.25x

INABN/A

Forward P/S (NTM)

EGRX0.05x

INABN/A

Revenue (TTM)

EGRX$258M

INAB$0

Revenue Growth (YoY)

EGRX-5.4%

INABN/A

Forward Rev Growth

EGRX0.0%

INAB1211.4%

Gross Margin (TTM)

EGRX69.9%

INAB0.0%

Operating Margin (TTM)

EGRX14.0%

INAB0.0%

EBITDA Margin (TTM)

EGRX24.5%

INAB0.0%

Net Margin (TTM)

EGRX4.7%

INAB0.0%

FCF Margin (TTM)

EGRX-3.6%

INABN/A

Net Income (TTM)

EGRX$12M

INAB$-19M

FCF (TTM)

EGRX$-9M

INAB$-15M

EPS (TTM)

EGRX$0.92

INAB-$0.96

ROE (TTM)

EGRX5.0%

INAB-9118.0%

ROA (TTM)

EGRX3.0%

INAB-7693.0%

ROIC (TTM)

EGRX3.9%

INAB-9006.0%

Cash

EGRX$15M

INAB$18M

Debt

EGRX$70M

INAB$126K

Net Cash/Debt

EGRX$-55M

INAB$18M

Current Ratio (TTM)

EGRX2.16x

INAB8.21x

Quick Ratio (TTM)

EGRX1.52x

INAB8.13x

Debt/Equity (TTM)

EGRX0.28x

INAB0.01x

Debt/Assets (TTM)

EGRX0.0%

INAB0.0%

Interest Coverage (TTM)

EGRXN/A

INABN/A

Net Debt/EBITDA (TTM)

EGRX0.00x

INAB0.00x

Beta

EGRX0.88

INAB0.24

52W Performance

EGRX49.2%

INAB-44.4%

YTD Performance

EGRX185.3%

INAB-45.5%

% from 52W High

EGRX-74.9%

INAB-50.9%

% from 52W Low

EGRX88081.8%

INAB52.3%

Asset Turnover (TTM)

EGRX0.64x

INAB0.00x

FCF Yield (TTM)

EGRX-74.5%

INAB-110.6%

Earnings Yield (TTM)

EGRX96.0%

INAB-141.4%

Dividend Yield (TTM)

EGRXN/A

INABN/A

Rule of 40

EGRX-9.0

INAB0.0

EV/GP/RG

EGRXN/A

INABN/A

Ticker research

View EGRX research View INAB research

Metric	EGRX Eagle Pharmaceuticals Inc	INAB IN8bio Inc
Market & Valuation
Market Cap	$13M	$13M
Enterprise Value	$67M	$-5M
Price	$0.97	$1.34
P/E Ratio	1.06x	N/A
P/S Ratio	0.05x	0.00x
EV/Sales	0.26x	0.00x
EV/EBITDA	1.07x	0.00x
P/B Ratio	0.05x	0.75x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.18x	0.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	0.25x	N/A
Forward P/S (NTM)	0.05x	N/A
Revenue & Growth
Revenue (TTM)	$258M	$0
Revenue Growth (YoY)	-5.4%	N/A
Forward Rev Growth	0.0%	1211.4%
Profitability
Gross Margin (TTM)	69.9%	0.0%
Operating Margin (TTM)	14.0%	0.0%
EBITDA Margin (TTM)	24.5%	0.0%
Net Margin (TTM)	4.7%	0.0%
FCF Margin (TTM)	-3.6%	N/A
Net Income (TTM)	$12M	$-19M
FCF (TTM)	$-9M	$-15M
EPS (TTM)	$0.92	-$0.96
ROE (TTM)	5.0%	-9118.0%
ROA (TTM)	3.0%	-7693.0%
ROIC (TTM)	3.9%	-9006.0%
Financial Health
Cash	$15M	$18M
Debt	$70M	$126K
Net Cash/Debt	$-55M	$18M
Current Ratio (TTM)	2.16x	8.21x
Quick Ratio (TTM)	1.52x	8.13x
Debt/Equity (TTM)	0.28x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	0.24
52W Performance	49.2%	-44.4%
YTD Performance	185.3%	-45.5%
% from 52W High	-74.9%	-50.9%
% from 52W Low	88081.8%	52.3%
Efficiency & Yields
Asset Turnover (TTM)	0.64x	0.00x
FCF Yield (TTM)	-74.5%	-110.6%
Earnings Yield (TTM)	96.0%	-141.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-9.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View EGRX research	View INAB research